177 completed, 46 terminated, 11 active not recruiting, 10 unknown. 155 Phase 2, 111 Phase 1, 24 Phase 3, 6 Phase 4, 2 Early Phase 1.
Follow RAD001: new trials by email Literature Review of RAD001 trials Research Report on RAD001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer Biospecimen Collection, Computed Tomography, Elacestrant - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 50 | 2026-12-18 | 2026-06-09 |
| Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma Doxorubicin, Doxorubicin Hydrochloride, Drug Delivery Microdevice - Metastatic Sarcoma, Recurrent Sarcoma | Not applicable | Recruiting | M.D. Anderson Cancer Center | 20 | 2025-02-25 | 2026-08-11 |
| Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. Everolimus, Elacestrant, Placebo - Advanced Breast Cancer, ER-positive Breast Cancer | Phase 3 | Recruiting | MedSIR | 300 | 2024-12-05 | 2026-08-24 |
| Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial Biospecimen Collection, Cabozantinib, Computed Tomography - Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 100 | 2024-01-12 | 2026-10-16 |
| A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) Everolimus - Renal Angiomyolipoma | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 4 | 2023-05-01 | 2026-09-17 |
| Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors Biospecimen Collection, Computed Tomography, Everolimus - Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor | Phase 2 | Recruiting | National Cancer Institute (NCI) | 70 | 2023-02-03 | 2026-10-19 |
| Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer Cabozantinib, Everolimus, Lenvatinib - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 90 | 2022-02-16 | 2026-09-14 |
| DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies DFF332, RAD001, PDR001 - Carcinoma, Renal Cell | Phase 1 | Terminated | Novartis Pharmaceuticals | 40 | 2021-11-30 | 2026-03-03 |
| Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer Trastuzumab, Pertuzumab, Nab paclitaxel - HER2+ Breast Cancer | Phase 3 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 120 | 2021-01-01 | 2022-06-23 |
| Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) Everolimus, Trametinib - Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma | Phase 1 | Recruiting | University of California, San Francisco | 50 | 2020-12-09 | 2026-08-18 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors Everolimus, Lenvatinib - Advanced Carcinoid Tumor, Digestive System Neuroendocrine Neoplasm | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 36 | 2019-07-30 | 2026-09-18 |
| Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy Everolimus, Laboratory Biomarker Analysis, Survey Administration - Salivary Gland Dysfunction, Xerostomia | Early Phase 1 | Terminated | University of Arizona | 2 | 2018-05-04 | 2019-12-02 |
| Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors Everolimus, Laboratory Biomarker Analysis, Pharmacological Study - CNS Embryonal Tumor, Not Otherwise Specified, Malignant Glioma | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 22 | 2018-01-13 | 2021-08-27 |
| Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation Everolimus, Neratinib, Palbociclib - Advanced Malignant Solid Neoplasm, EGFR Gene Amplification | Phase 1 | Terminated | M.D. Anderson Cancer Center | 84 | 2017-10-31 | 2026-07-22 |
| A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor Everolimus, Exemestane, Everolimus Placebo - Advanced Breast Cancer | Phase 2 | Completed | Novartis Pharmaceuticals | 159 | 2017-09-15 | 2024-01-23 |
| Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment everolimus - Tuberous Sclerosis Complex | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 206 | 2017-08-23 | 2026-08-21 |
| A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma Everolimus, Letrozole, Ribociclib - Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 90 | 2017-08-18 | 2026-05-22 |
| Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) Ribociclib, Everolimus - Soft Tissue Sarcoma | Phase 2 | Active not recruiting | Fox Chase Cancer Center | 48 | 2017-08-08 | 2026-05-22 |
| RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome RAD001, Placebo - PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome | Phase 1 / Phase 2 | Completed | Boston Children's Hospital | 46 | 2017-06-12 | 2025-02-17 |
Showing 20 of 258. Sign in to see all of them.
Breast Neoplasms (41) · Carcinoma, Renal Cell (25) · Neoplasm Metastasis (21) · Neuroendocrine Tumors (15) · Kidney Neoplasms (14) · Neoplasms (12) · Tuberous Sclerosis (11) · Hodgkin Disease (9) · Lung Neoplasms (9) · Lymphoma, Mantle-Cell (9) · Carcinoma, Hepatocellular (8) · Carcinoma, Non-Small-Cell Lung (8) · Lymphoma, Large B-Cell, Diffuse (8) · Pancreatic Neoplasms (8) · Prostatic Neoplasms (8)
Novartis Pharmaceuticals (59) · M.D. Anderson Cancer Center (31) · Dana-Farber Cancer Institute (14) · Emory University (11) · Mayo Clinic (8) · National Cancer Institute (NCI) (8) · SCRI Development Innovations, LLC (7) · Children's Hospital Medical Center, Cincinnati (4) · Fox Chase Cancer Center (4) · Swiss Cancer Institute (4) · Asan Medical Center (3) · Seoul National University Hospital (3) · University of California, Davis (3) · Vanderbilt-Ingram Cancer Center (3) · City of Hope Medical Center (2)
United States (196) · Germany (36) · France (33) · Italy (29) · Spain (26) · South Korea (23) · Netherlands (21) · Australia (20) · Belgium (20) · United Kingdom (20) · Canada (19) · Japan (16) · Thailand (16) · Taiwan (14) · China (13)
Amado Zurita, MD (2) · Filip Janku (2) · Herbert I Hurwitz, MD (2) · Ingrid Mayer, MD (2) · Jean-Francois Dufour, MD (2) · John D. Hainsworth, M.D. (2) · John D. Hainsworth, MD (2) · Mustafa Sahin, MD, PhD (2) · Nabil F. Saba, MD (2) · Robert J Amato, DO (2) · Sunil Sharma, MD (2) · Suresh Ramalingam, MD (2) · Taofeek Owonikoko, MD, PhD (2)
PMID 29023494, PMID 19192962, PMID 21730275, PMID 25682485, PMID 30053159, PMID 33560090, PMID 18653228, PMID 19047305, PMID 19497063, PMID 19549709, PMID 19745764, PMID 19790150, PMID 20194812, PMID 20368560, PMID 20564157, PMID 20630061, PMID 21047224, PMID 21306238, PMID 21410393, PMID 22119496, PMID 22149876, PMID 22209391, PMID 22262746, PMID 22297244, PMID 22315486, PMID 22342553, PMID 22736724, PMID 22824201, PMID 22928480, PMID 23158522, PMID 23180114, PMID 23187897, PMID 23219086, PMID 23325902, PMID 23404211, PMID 23475104, PMID 23580238, PMID 23582881, PMID 23733802, PMID 23798472, PMID 23962028, PMID 23969699, PMID 24037083, PMID 24043745, PMID 24156027, PMID 24158787, PMID 24327334, PMID 24332215, PMID 24615500, PMID 24669015
2008 (10), 2009 (5), P30CA015083 (4), P30CA016672 (3), U10CA180821 (3), P30CA043703 (2), U10CA031946 (2), 2004 (1), K23CA121994 (1), N01CM00038 (1), N01CM00039 (1), N01CM62202 (1), P30CA008748 (1), P30CA023074 (1), P30CA068485 (1)